Oxyfedrine is an orally active β-adrenoreceptor agonist. Oxyfedrine is a vasodilator that reduces coronary vessels tonicity that can be used in cardiovascular disease research[1] [2].

Oxyfedrine (50 μM, 48 h) suppresses aldehyde dehydrogenase (ALDH) activity in HCT116 and HSC-4 cells [1]. Oxyfedrine (50 μM, 48 h) acts as a sensitizer for GSH-depleting agents, and induces cell death in HCT116 and HSC-4 cells when with the drug combinations [1]. Oxyfedrine (0-1 μg/mL) inhibits spontaneous myogenic activity in rat isolated portal vein [4].

Oxyfedrine (14 mg/kg, p.o., for 3-4 weeks) shows anti-anginal action in cats [2]. Oxyfedrine (10 mg/kg, i.p., HCT116 cell xenograft mice) suppresses tumor growth when combined with sulfasalazine (SSZ, 350 mg/kg, i.p.) [1]. Oxyfedrine (1 mg/kg, i.v.) decreases the arterial and venous blood high blood viscosity (HBV) in ice water stress rats [3]. Animal Model: Cats [2] Dosage: 14 mg/kg Administration: Oral administration (p.o.), for 3-4 weeks. Result: Decreased systolic and diastolic blood pressures, increased heart rate and cardiac output.